Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy

NCT ID: NCT03214393

Last Updated: 2017-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-01

Study Completion Date

2018-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Relation of certain maternal serum antibodies to Doppler changes will be studied in cases suffering from hypertension with pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Assessment will be done for maternal serum anti-beta 2 glycoprotein 1 antibodies and anticardiolipin antibodies in cases of preeclampsia after 32 weeks of pregnancy. In addition, fetal Doppler changes will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-Eclampsia

pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler

Doppler

Intervention Type DIAGNOSTIC_TEST

Doppler will be done to pregnant women with Pre-Eclampsia

serum antibodies

Intervention Type DIAGNOSTIC_TEST

serum antibodies will be measured for pregnant women with Pre-Eclampsia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doppler

Doppler will be done to pregnant women with Pre-Eclampsia

Intervention Type DIAGNOSTIC_TEST

serum antibodies

serum antibodies will be measured for pregnant women with Pre-Eclampsia

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women 32 weeks or more gestational age
* Pre-eclampsia
* Singleton pregnancy

Exclusion Criteria

* Intrauterine fetal death
* Fetus with apparent congenital anomalies
* Pregnant females with other medical disorders
* History of essential hypertension.
* History of antepartum hemorrhage.
* History of rupture of membranes.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Doaa Shafie Belal

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Doaa Sh Belal, MD

Role: PRINCIPAL_INVESTIGATOR

Cairo U

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Obstetrics and Gynecology

Cairo, Greater Cairo, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Doaa Sh Belal, MD

Role: CONTACT

0020223682030

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Doaa Belal, MD

Role: primary

0020223682030

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3650

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Progestrone and Doppler Indices
NCT03292939 COMPLETED PHASE2/PHASE3
Diastolic Dysfunction 2025
NCT07190846 COMPLETED
Fetal Cardiac Function
NCT06381258 COMPLETED